December 01, 2019
1 min read

Top stories from VIVA: Peripheral DES, drug-coated balloons and more

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Healio and Cardiology Today present meeting highlights from VIVA 19 in Las Vegas. Top stories included the latest from the IMPERIAL head-to-head comparison of two peripheral drug-eluting stents, a low-dose paclitaxel-coated balloon, new advances for patients with critical limb ischemia and more.


IMPERIAL: Peripheral DES similar in patency, different in TLR at 2 years

A peripheral drug-eluting stent with a polymer coating conferred lower rates of target lesion revascularization compared with a peripheral DES without a polymer coating, according to 2-year results from the IMPERIAL trial. Read more


New advances offer hope to patients with CLI

While critical limb ischemia presents many challenges, numerous new technologies and techniques are being developed to help this population, Peter Schneider, MD, said at VIVA 19. Read more


Mortality not different at 5 years in patients treated with DES vs. controls

There were no significant differences in mortality at 5 years between patients with peripheral artery disease assigned a drug-eluting stent and those assigned a bare-metal stent or percutaneous transluminal angioplasty, according to new data presented at VIVA 19. Read more


Peripheral stent beneficial in common femoral artery stenosis at 2 years

A repuncturable vascular mimetic peripheral stent system was safe and effective at 2 years in patients with common femoral artery disease, according to new data from the VMI-CFA study. Read more


RANGER II SFA: Low-dose paclitaxel-coated balloon superior to PTA at 1 year

A low-dose paclitaxel-coated balloon was superior to percutaneous transluminal angioplasty for treatment of femoropopliteal disease, according to results from a prespecified interim 1-year analysis from the RANGER II SFA trial presented at VIVA 19. Read more